Financial Report: AbbVie

AbbVie

4Q Revenues: $8.7 billion (+5%)

4Q Earnings: $2.8 billion (loss of $1.8 billion 4Q18)   

FY Revenues: $33.3 billion (+2%)

FY Earnings: $7.9 billion (+39%)

Comments: U.S. HUMIRA sales were $4.0 billion in the quarter, up 10%. Internationally, HUMIRA revenues were $948 million, down 27% due to biosimilar competition. Global IMBRUVICA revenues were $1.3 billion, an increase of 29%, with U.S. sales of $1.1 billion and international profit sharing of $223 million. Global VENCLEXTA sales were $251 million. Global net revenues from the hematologic oncology portfolio were $1.5 billion, an increase of 37%. Global SKYRIZI sales were $216 million and global RINVOQ net revenues were $33 million. AbbVie and Allergan announced agreements to divest Brazikumab and Zenpep. The pending AbbVie/Allergan transaction is expected to close 1Q20.